Colorectal Neoplasms Clinical Trial
Official title:
Adding Family History of Colorectal Cancer to the FIT-based Screening Program in a Dutch Colorectal Cancer Population Sample
The aim of this study is to identify more persons with advanced neoplasia in the current national CRC screening, by adding data on family history of CRC (using a validated online questionnaire) to FIT. In addition, the aim is to identify those persons and their family members who should not be participating in a FIT based screening but receive surveillance colonoscopies instead, because of a familial CRC syndrome. It is aimed to increase detection without affecting participation, thereby increasing the yield of screening.
This is a prospective CRC population-based screening trial, using FIT and a family history
questionnaire, inviting those with a positive FIT, a familial CRC syndrome, or both for
colonoscopy.
All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online
family history questionnaire. Answers from the questionnaire are compared with the Dutch
criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a
potential familial risk for CRC. Invitees are invited to perform both tests, but if they only
perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml)
and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist
will be referred for colonoscopy.
The investigators will compare the diagnostic yield, participation rate, and positive
predictive value for two strategies: referral for colonoscopy based on FIT and family history
versus referral for colonoscopy based on FIT-only.
The sample size is justified by the anticipated gain in diagnostic yield from combining
FIT-only with family history screening. With a sample size of 6.000 persons the investigators
expect to detect 130 persons with advanced neoplasia after a positive FIT (21.7 per 1.000
invitees). By adding the family history questionnaire, the investigators anticipate detecting
an additional number of 11 persons with advanced neoplasia, resulting in a yield of combined
FIT-based and family history screening of 141 persons with advanced neoplasia (23.5 per 1.000
invitees), which is an increase of 1.8 per 1.000 invitees. Using the McNemar test with the
significance level set at 5%, there is a power of 91% to show that the gain in diagnostic
yield is statistically significant. Previous CRC test screening studies using FIT showed that
participation rates are approximately 60% in a first screening round. The participation rate
in the Dutch national CRC screening in 2014 (the first year of introduction) was even higher,
68%. The investigators expect that 80% of these persons will fill out the familial risk
questionnaire, resulting in 3.264 persons who perform both tests. As the investigators
recommend invitees to perform the questionnaire in addition to FIT, the investigators assume
that the percentage of persons only filling out the questionnaire and not performing FIT are
negligible. Based on previous screening studies using a FIT positivity cut-off value of 50 ng
Hb/mL for the OC-Sensor, it is assumed that 8% of these participants have a positive FIT
result. In the current Dutch screening program, a different FIT is used (FOB-Gold) with a
cut-off value of 275 ng Hb/ml. The FIT positivity rate with this test and with this cut-off
value is unknown. However, a governmental announcement recently reported that the positivity
rate is expected to remain 8% with this cut-off value. Therefore, the investigators expect
326 FIT positives in this study (8% of 4.080). Based on previous studies, approximately 40%
of all persons with a positive FIT result will have advanced neoplasia. In our sample this
concerns 130 persons. The percentage of persons with a familial CRC risk requiring
surveillance colonoscopies in a screening population varies between 2.3% and 4%. Differences
in the definition of an increased familial CRC risk could explain the variability in reported
numbers. As the investigators are using a relatively large range in criteria for fulfilling
the definition of a familial CRC risk, the highest reported percentage (4%) is assumed, which
concerns 131 persons. The previously developed family history questionnaire has a sensitivity
of 90% and 100% in identifying those persons qualifying for referral, in two subsequent
validation phases respectively. For the purpose of this study, this validated questionnaire
is adjusted to the recently renewed referral criteria. The investigators make the assumption
that the questionnaire can identify all persons with a familial CRC syndrome based on
referral criteria. Persons with a familial CRC syndrome who do not fulfill these criteria
will be missed. This concerns an unknown number and will not be taken into account. A
previous screening study showed that 6% of those with a positive FIT have an increased
familial CRC risk. One can calculate that 3.8% of persons with a negative FIT have a familial
CRC risk: 4% minus 6% of 8% (FIT positives), divided by 92% (FIT negatives). If one assumes
that there is no difference in familial CRC risk between those who do and those who do not
fill out the questionnaire, this involves 114 of 3.264 persons. Based on unpublished data by
this research group it is estimated that 10% of those with a negative FIT have a familial CRC
risk: 11 persons (10% of 114). A similar percentage was found in another screening study.
Additionally, all participants with a familial CRC syndrome will be offered surveillance
recommendations. In this sample, 131 persons are estimated to have a familial CRC syndrome.
Of these, 16 persons (12%) will undergo a colonoscopy due to a positive FIT (6% of 8% FIT
positives) and their familial CRC risk could be addressed at their visit to a colonoscopy
center. The other 115 persons (88%) are expected to have a negative FIT and these persons
(and their family members) would otherwise be unlikely to be identified as having a familial
CRC syndrome.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04552093 -
Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
|
Phase 2/Phase 3 | |
| Completed |
NCT04192565 -
A Prospective Investigation of the ColubrisMX ELS System
|
N/A | |
| Completed |
NCT05178745 -
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
|
||
| Recruiting |
NCT03561350 -
Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
|
||
| Recruiting |
NCT06128798 -
Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery.
|
N/A | |
| Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
| Completed |
NCT03631407 -
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
|
Phase 2 | |
| Withdrawn |
NCT04192929 -
Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy
|
N/A | |
| Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
| Terminated |
NCT02842580 -
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT02889679 -
Underwater Resection of Non-pedunculated Colorectal Lesions
|
N/A | |
| Completed |
NCT02564835 -
Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer
|
N/A | |
| Completed |
NCT02149108 -
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
|
Phase 3 | |
| Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
| Completed |
NCT02599103 -
The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects
|
N/A | |
| Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
| Completed |
NCT01669109 -
Hatha Yoga for Patients With Colorectal Cancer
|
N/A | |
| Recruiting |
NCT01428752 -
Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer
|
N/A | |
| Completed |
NCT01978717 -
General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer
|
N/A | |
| Completed |
NCT01877018 -
Colorectal Cancer Screening in Primary Care
|
N/A |